Clinical Trial Update: Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab plus nab-paclitaxel in metastatic urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Urothelial Carcinoma | Phase 2 | Status: COMPLETED